Departments of Pediatrics.
Departments of Pediatrics.
J Heart Lung Transplant. 2021 Apr;40(4):298-306. doi: 10.1016/j.healun.2020.12.008. Epub 2020 Dec 29.
Indications for a heart‒liver transplantation (HLT) for Fontan recipients are not well defined. We compared listing characteristics, post-operative complications, and post-transplant outcomes of Fontan recipients who underwent HLT with those of patients who underwent heart-only transplantation (HT). We hypothesized that patients who underwent HLT have increased post-operative complications but superior survival outcomes compared with patients who underwent HT.
We performed a retrospective review of Fontan recipients who underwent HLT or HT at a single institution. Characteristics at the time of listing, including the extent of liver disease determined by laboratory, imaging, and biopsy data, were compared. Post-operative complications were assessed, and the Kaplan‒Meier survival method was used to compare post-transplant survival. Univariate regression analyses were performed to identify the risk factors for increased mortality and morbidity among patients who underwent HT.
A total of 47 patients (9 for HLT, 38 for HT) were included. Patients who underwent HLT were older, were more likely to be on dual inotrope therapy, and had evidence of worse liver disease. Whereas ischemic time was longer for the group who underwent HLT, post-operative complications were similar. Over a median post-transplant follow-up of 17 (interquartile range: 5-52) months, overall mortality for the cohort was 17%; only 1 patient who underwent HLT died (11%) vs 7 patients who underwent HT (18%) (p = 0.64). Among patients who underwent HT, cirrhosis on pre-transplant imaging was associated with worse outcomes.
Despite greater inotrope need and more severe liver disease at the time of listing, Fontan recipients undergoing HLT have post-transplant outcomes comparable with those of patients undergoing HT. HLT may offer a survival benefit for Fontan recipients with liver disease.
心脏-肝脏联合移植(HLT)用于 Fontan 受体的适应证尚未明确。我们比较了接受 HLT 和仅心脏移植(HT)的 Fontan 受体患者的术前特征、术后并发症和移植后结局。我们假设与接受 HT 的患者相比,接受 HLT 的患者术后并发症更多,但生存结局更好。
我们对在单中心接受 HLT 或 HT 的 Fontan 受体进行了回顾性研究。比较了术前特征,包括实验室、影像学和活检数据确定的肝脏疾病严重程度。评估了术后并发症,并采用 Kaplan-Meier 生存法比较移植后生存情况。采用单因素回归分析确定了 HT 患者死亡率和发病率增加的危险因素。
共纳入 47 例患者(9 例行 HLT,38 例行 HT)。行 HLT 的患者年龄更大,更可能接受双正性肌力药物治疗,且有更严重的肝脏疾病证据。虽然 HLT 组的缺血时间较长,但术后并发症相似。中位随访 17 个月(四分位距:5-52)后,队列的总死亡率为 17%;仅 1 例行 HLT 的患者死亡(11%),而 7 例行 HT 的患者死亡(18%)(p=0.64)。在接受 HT 的患者中,移植前影像学显示肝硬化与预后不良相关。
尽管在术前需要更多的正性肌力药物和更严重的肝脏疾病,但接受 HLT 的 Fontan 受体患者的移植后结局与接受 HT 的患者相当。HLT 可能为患有肝脏疾病的 Fontan 受体带来生存获益。